FinHER Regimen Outcomes for HER2-Positive Breast Cancer in South India

A retrospective audit of 100 patients with locally advanced HER2-positive breast cancer treated with a neoadjuvant FinHer regimen in a resource-limited setting. The dataset includes pathological complete response rates and 5-year disease-free and overall survival outcomes. It was authored by Anoop T. M. and last updated in May 2026.

Use Cases

• Analyze predictors of pathological complete response based on hormone receptor status and molecular subtype.
• Model survival outcomes (DFS and OS) based on disease stage (III vs. oligometastatic).
• Evaluate the efficacy of a short-course trastuzumab regimen in a neoadjuvant setting.
• Compare treatment response rates between HER2-enriched and luminal B HER2-positive subtypes.

Strengths

• Includes 100 patient records with a defined cohort of 76 stage III and 24 oligometastatic patients.
• Reports specific statistical outcomes, including a 30% pCR rate and hazard ratios for survival.
• Contains results from univariate and multivariate analyses identifying stage as a significant predictor.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to the South Indian population studied.

Provenance

Source

figshare

Collection Method

Retrospective audit of patients receiving neoadjuvant chemotherapy following the FinHer protocol.

Freshness

Last updated 2026-05-18 04:10:39; freshness should be verified.

Geography

South Indian population